IP Library Granted Patent US 8,632,512
Granted Patent B2
US 8,632,512 · App. 12/757,562 · Granted Jan 21, 2014

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,632,512
App. No.
12/757,562
Granted
Jan 21, 2014
Kind
B2
Abstract

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.

Claims (20)

1. A wound dressing for applying treatment to a tissue site comprising:

a porous polyurethane material comprising open-cell foam comprising a plurality of flow channels formed from pores within the open-cell foam and sized to distribute reduced pressure through the porous polyurethane material, the porous polyurethane material adapted to receive reduced pressure and having a contact surface adapted to be positioned proximate the tissue site; and

a composition comprising gelatin coated on at least a portion of the contact surface and infused within a portion of the plurality of flow channels adjacent the contact surface of the porous polyurethane material.

2. The wound dressing of claim 1 , wherein the concentration of the gelatin is at least 4% w/w.

3. The wound dressing of claim 1 , further comprising an antimicrobial agent, a growth factor, a proteinase inhibitor, a chelating agent or a preservative.

4. The wound dressing of claim 3 , wherein the antimicrobial agent is non-ionic silver, polyhexamethylene biguanide, chlorhexidine, benzalconium chloride or triclosan.

5. The wound dressing of claim 3 , wherein the chelating agent is ethylenediaminetetraacetic acid.

6. A reduced pressure therapy system comprising:

a porous polyurethane material comprising open-cell foam comprising a plurality of flow channels formed from pores within the open-cell foam and sized to distribute reduced pressure through the porous polyurethane material, the porous polyurethane material adapted to receive reduced pressure and having a contact surface adapted to be positioned proximate a tissue site;

composition comprising gelatin coated on at least a portion of the contact surface and infused within a portion of the plurality of flow channels adjacent the contact surface;

a drape adapted to be positioned over the porous polyurethane material to maintain a sealable space over the tissue site; and

a source of a reduced pressure in fluid communication with the sealable space to deliver the reduced pressure through the drape to the sealable space and the porous polyurethane material.

7. The system of claim 6 , wherein the reduced pressure applied to the porous polyurethane material causes an increased area of contact between the porous polyurethane, material and the tissue, thereby increasing exposure of the tissue to the gelatin.

8. The system of claim 7 , wherein the inflammatory activity in the tissue is reduced by causing the increased area of contact.

9. The system of claim 7 , wherein the reduced pressure compresses the porous polyurethane material against the tissue to form the increased area of contact.

10. The system of claim 6 , wherein inflammatory activity in the tissue is reduced by removal of body-liquid from the tissue into the flow channels and by the exposure of the body-liquid in the flow channels to the gelatin.

11. The system of claim 6 , further comprising a manifold adapted to provide reduced pressure to the porous polyurethane material and the tissue.

12. The wound dressing of claim 1 , wherein the gelatin comprises a bloom value of between about 150-300 g.

13. The wound dressing of claim 1 , wherein the gelatin comprises a bloom value of between about 200-250 g.

14. The wound dressing of claim 1 , wherein the gelatin comprises a bloom value of about 225 g.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066445/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064730/0218 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2015
From: SANDERS, BLANE
To: KCI LICENSING, INC.
Reel/Frame 036076/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2010
From: ZIMNITSKY, DMITRY; FINKBINER, JENNY
To: KCI LICENSING, INC.
Reel/Frame 024478/0864 →